181 related articles for article (PubMed ID: 34032761)
1. KIF4A as a novel prognostic biomarker in cholangiocarcinoma.
Zhang DY; Ma SS; Sun WL; Lv XCH; Lu Z
Medicine (Baltimore); 2021 May; 100(21):e26130. PubMed ID: 34032761
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M expression and
Liu Q; Lan T; Song Y; Cai J; Yu X; Chen W
Aging (Albany NY); 2020 Nov; 12(21):21518-21543. PubMed ID: 33216732
[TBL] [Abstract][Full Text] [Related]
3. Revision of potential prognostic markers of cholangiocarcinoma for clinical practice.
Saengboonmee C; Obchoei S; Sawanyawisuth K; Wongkham S
Expert Rev Anticancer Ther; 2023 May; 23(5):517-530. PubMed ID: 37052887
[TBL] [Abstract][Full Text] [Related]
4. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma.
Liu CH; Huang Q; Jin ZY; Xie F; Zhu CL; Liu Z; Wang C
J Cancer Res Ther; 2018 Jan; 14(1):220-225. PubMed ID: 29516989
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of DNA Topoisomerase II Alpha (TOP2A) in Cholangiocarcinoma.
Ong KH; Lai HY; Sun DP; Chen TJ; Huang SK; Tian YF; Chou CL; Shiue YL; Chan TC; Li CF; Kuo YH
Front Biosci (Landmark Ed); 2023 Apr; 28(4):75. PubMed ID: 37114547
[TBL] [Abstract][Full Text] [Related]
8. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.
Walter D; Hartmann S; Waidmann O
Z Gastroenterol; 2017 Jun; 55(6):575-581. PubMed ID: 28376540
[TBL] [Abstract][Full Text] [Related]
9. PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.
Chen Z; Yu M; Yan J; Guo L; Zhang B; Liu S; Lei J; Zhang W; Zhou B; Gao J; Yang Z; Li X; Zhou J; Fan J; Ye Q; Li H; Xu Y; Xiao Y
Front Immunol; 2021; 12():647209. PubMed ID: 33841428
[TBL] [Abstract][Full Text] [Related]
10. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.
Zhou Z; Ma J
Cancer Biomark; 2019; 24(2):173-181. PubMed ID: 30594918
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel mutation gene signature HAMP for cholangiocarcinoma through comprehensive TCGA and GEO data mining.
Wang Z; Du Y
Int Immunopharmacol; 2021 Oct; 99():108039. PubMed ID: 34426102
[TBL] [Abstract][Full Text] [Related]
12. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
13. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ
Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181
[TBL] [Abstract][Full Text] [Related]
14. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.
Huang QX; Cui JY; Ma H; Jia XM; Huang FL; Jiang LX
Cancer Gene Ther; 2016; 23(2-3):48-53. PubMed ID: 26679756
[TBL] [Abstract][Full Text] [Related]
15. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
[TBL] [Abstract][Full Text] [Related]
16. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.
Jiang Y; Zheng X; Jiao D; Chen P; Xu Y; Wei H; Qian Y
EBioMedicine; 2019 Feb; 40():422-431. PubMed ID: 30638862
[TBL] [Abstract][Full Text] [Related]
17. LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma.
Jiang XM; Li ZL; Li JL; Zheng WY; Li XH; Cui YF; Sun DJ
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1242-1247. PubMed ID: 28387907
[TBL] [Abstract][Full Text] [Related]
18. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic analysis the expression and clinical significance of CDRT15 in cholangiocarcinoma using TCGA database.
Yu T; Zhang T; Zhao L; Li K; Li J; Yu A
Medicine (Baltimore); 2023 Aug; 102(31):e34602. PubMed ID: 37543771
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional profiles of peripheral blood leukocytes identify patients with cholangiocarcinoma and predict outcome.
Subimerb C; Wongkham C; Khuntikeo N; Leelayuwat C; McGrath MS; Wongkham S
Asian Pac J Cancer Prev; 2014; 15(10):4217-24. PubMed ID: 24935374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
